CEL-SCI Corporation
CEL-SCI Corporation
Your view on CVM
Overview
What the company does, where it operates, and who runs it.
About CEL-SCI Corporation
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Geert R. Kersten
- Headquarters
- 8229 Boone Boulevard, Vienna, VA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Geert R. Kersten
- Headquarters
- 8229 Boone Boulevard, Vienna, VA, US
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer.
Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.
The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus.
CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for CEL-SCI Corporation from FRC's valuation model, read against the market price. CVM last traded at $1.66; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for CEL-SCI Corporation. Starting points for CEL-SCI Corporation: EPS -$1.87, beta 0.62 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for CEL-SCI Corporation. CEL-SCI Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for CEL-SCI Corporation. Trailing twelve-month EPS for CEL-SCI Corporation stands at -$1.87. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Analyst Ratings
- Strong Buy0
- Buy6
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrMar 2011 | Next QtrMar 2013 | Current YearFY Sep 2016 | Next YearFY Sep 2017 |
|---|---|---|---|---|
| Avg. estimate | -$11.00 | -$5.00 | -$217.50 | -$34.20 |
| Low estimate | -$13.20 | -$6.00 | -$217.50 | -$34.20 |
| High estimate | -$8.80 | -$4.00 | -$217.50 | -$34.20 |
| No. of analysts | 13 | 10 | 1 | 1 |
| Year-ago EPS | — | — | — | — |
| Growth | — | — | — | — |
Revenue Estimate
| Revenue | Current QtrMar 2011 | Next QtrMar 2013 | Current YearFY Sep 2016 | Next YearFY Sep 2017 |
|---|---|---|---|---|
| Avg. estimate | $48196.00 | $30000.00 | $1.00M | $100000.00 |
| Low estimate | $38556.00 | $24000.00 | $1.00M | $100000.00 |
| High estimate | $57835.00 | $36000.00 | $1.00M | $100000.00 |
| No. of analysts | 13 | 10 | 1 | 1 |
| Year-ago revenue | — | — | — | — |
| Growth | — | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 17, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for CEL-SCI Corporation. CEL-SCI Corporation has reported as a listed company since 1983. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ALGSAligos Therapeutics, Inc.Biotechnology$10M
- BRNSBarinthus Biotherapeutics plcBiotechnology$30M
- INMBINmune Bio, Inc.Biotechnology$29M
- OKUROnKure Therapeutics, Inc.Biotechnology$111M
- PDSBPDS Biotechnology CorporationBiotechnology$52M
More Biotechnology companies
- ACADACADIA Pharmaceuticals Inc.NASDAQ$3.2B
- ACETAdicet Bio, Inc.NASDAQ$26M
- ACHFFArch Biopartners Inc.OTC$41M
- ACHVAchieve Life Sciences, Inc.NASDAQ$698M
- ACIUAC Immune S.A.NASDAQ$217M
ETFs holding CEL-SCI Corporation
% of the fund
- VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
- VXFVanguard Extended Market ETF$30.2B in assets0.00%
- VUN.TOVanguard U.S. Total Market Index ETF$20.1B in assets0.00%
- VEQT.TOVanguard All-Equity ETF Portfolio$17.6B in assets0.00%
Largest holders first, then the funds most concentrated in CVM.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold CEL-SCI Corporation, and how their positions are changing. At a $29.2M market value, institutional positions materially move CEL-SCI Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by CEL-SCI Corporation executives and directors. Shares of CEL-SCI Corporation have traded between $1.98 and $32.70 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for CEL-SCI Corporation. Coverage tracks CEL-SCI Corporation within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of CEL-SCI Corporation.